{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:58:09Z","timestamp":1790693889997,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We previously showed that curcumin, a phytopolyphenol found in turmeric (<jats:italic>Curcuma longa<\/jats:italic>), targets a series of enzymes in the ROS metabolic pathway, induces irreversible growth arrest, and causes apoptosis. In this study, we tested Pentagamavunon-1 (PGV-1), a molecule related to curcumin, for its inhibitory activity on tumor cells <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. PGV-1 exhibited 60 times lower GI<jats:sub>50<\/jats:sub> compared to that of curcumin in K562 cells, and inhibited the proliferation of cell lines derived from leukemia, breast adenocarcinoma, cervical cancer, uterine cancer, and pancreatic cancer. The inhibition of growth by PGV-1 remained after its removal from the medium, which suggests that PGV-1 irreversibly prevents proliferation. PGV-1 specifically induced prometaphase arrest in the M phase of the cell cycle, and efficiently induced cell senescence and cell death by increasing intracellular ROS levels through inhibition of ROS-metabolic enzymes. In a xenograft mouse model, PGV-1 had marked anti-tumor activity with little side effects by oral administration, whereas curcumin rarely inhibited tumor formation by this administration. Therefore, PGV-1 is a potential therapeutic to induce tumor cell apoptosis with few side effects and low risk of relapse.<\/jats:p>","DOI":"10.1038\/s41598-019-51244-3","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T10:07:34Z","timestamp":1571220454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence"],"prefix":"10.1038","volume":"9","author":[{"given":"Beni","family":"Lestari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yoneda-Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsumoru","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiko","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0431-3456","authenticated-orcid":false,"given":"Masafumi","family":"Shionyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-5738","authenticated-orcid":false,"given":"Tsuyoshi","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-6322","authenticated-orcid":false,"given":"Edy","family":"Meiyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"51244_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674, https:\/\/doi.org\/10.1016\/j.cell.2011.02.013 (2011).","journal-title":"Cell"},{"key":"51244_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"51244_CR3","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1002\/cncr.26568","volume":"118","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian, H. et al. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 118, 3116\u20133122, https:\/\/doi.org\/10.1002\/cncr.26568 (2012).","journal-title":"Cancer"},{"key":"51244_CR4","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1002\/cncr.26196","volume":"117","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama, A., Cortes, J. E. & Kantarjian, H. M. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. Cancer 117, 5261\u20135270, https:\/\/doi.org\/10.1002\/cncr.26196 (2011).","journal-title":"Cancer"},{"key":"51244_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11, 1029\u20131035, https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3 (2010).","journal-title":"Lancet Oncol"},{"key":"51244_CR6","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3892\/etm.2015.2749","volume":"10","author":"D Perrone","year":"2015","unstructured":"Perrone, D. et al. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med 10, 1615\u20131623, https:\/\/doi.org\/10.3892\/etm.2015.2749 (2015).","journal-title":"Exp Ther Med"},{"key":"51244_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-3-14","volume":"3","author":"G Sa","year":"2008","unstructured":"Sa, G. & Das, T. Anti cancer effects of curcumin: cycle of life and death. Cell Div 3, 14, https:\/\/doi.org\/10.1186\/1747-1028-3-14 (2008).","journal-title":"Cell Div"},{"key":"51244_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/543040c","volume":"543","author":"M Heger","year":"2017","unstructured":"Heger, M. Drug screening: Don\u2019t discount all curcumin trial data. Nature 543, 40, https:\/\/doi.org\/10.1038\/543040c (2017).","journal-title":"Nature"},{"key":"51244_CR9","doi-asserted-by":"publisher","unstructured":"Zaidi, A., Lai, M. & Cavenagh, J. Long-term stabilisation of myeloma with curcumin. BMJ Case Rep 2017, https:\/\/doi.org\/10.1136\/bcr-2016-218148 (2017).","DOI":"10.1136\/bcr-2016-218148"},{"key":"51244_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20179-6","volume":"8","author":"YA Larasati","year":"2018","unstructured":"Larasati, Y. A. et al. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep 8, 2039, https:\/\/doi.org\/10.1038\/s41598-018-20179-6 (2018).","journal-title":"Sci Rep"},{"key":"51244_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2007.03.015","volume":"115","author":"EM Ellis","year":"2007","unstructured":"Ellis, E. M. Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol Ther 115, 13\u201324, https:\/\/doi.org\/10.1016\/j.pharmthera.2007.03.015 (2007).","journal-title":"Pharmacol Ther"},{"key":"51244_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12, 931\u2013947, https:\/\/doi.org\/10.1038\/nrd4002 (2013).","journal-title":"Nat Rev Drug Discov"},{"key":"51244_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.105","volume":"7","author":"E Panieri","year":"2016","unstructured":"Panieri, E. & Santoro, M. M. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis 7, e2253, https:\/\/doi.org\/10.1038\/cddis.2016.105 (2016).","journal-title":"Cell Death Dis"},{"key":"51244_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/541144a","volume":"541","author":"M Baker","year":"2017","unstructured":"Baker, M. Deceptive curcumin offers cautionary tale for chemists. Nature 541, 144\u2013145, https:\/\/doi.org\/10.1038\/541144a (2017).","journal-title":"Nature"},{"key":"51244_CR15","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","volume":"60","author":"KM Nelson","year":"2017","unstructured":"Nelson, K. M. et al. The Essential Medicinal Chemistry of Curcumin. J Med Chem 60, 1620\u20131637, https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00975 (2017).","journal-title":"J Med Chem"},{"key":"51244_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7314\/APJCP.2014.15.1.179","volume":"15","author":"E Meiyanto","year":"2014","unstructured":"Meiyanto, E. et al. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev 15, 179\u2013184 (2014).","journal-title":"Asian Pac J Cancer Prev"},{"key":"51244_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-017-0025-3","volume":"7","author":"N Allocati","year":"2018","unstructured":"Allocati, N., Masulli, M., Di Ilio, C. & Federici, L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis 7, 8, https:\/\/doi.org\/10.1038\/s41389-017-0025-3 (2018).","journal-title":"Oncogenesis"},{"key":"51244_CR18","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1016\/S0021-9258(19)42083-8","volume":"249","author":"WH Habig","year":"1974","unstructured":"Habig, W. H., Pabst, M. J. & Jakoby, W. B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249, 7130\u20137139 (1974).","journal-title":"J Biol Chem"},{"key":"51244_CR19","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1210\/jc.2003-031734","volume":"89","author":"JM Dziba","year":"2004","unstructured":"Dziba, J. M. & Ain, K. B. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 89, 2127\u20132135, https:\/\/doi.org\/10.1210\/jc.2003-031734 (2004).","journal-title":"J Clin Endocrinol Metab"},{"key":"51244_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7, 27\u201331, https:\/\/doi.org\/10.4103\/0976-0105.177703 (2016).","journal-title":"J Basic Clin Pharm"},{"key":"51244_CR21","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/leu.2013.13","volume":"27","author":"S Bouchet","year":"2013","unstructured":"Bouchet, S. et al. From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome. Leukemia 27, 1757\u20131759, https:\/\/doi.org\/10.1038\/leu.2013.13 (2013).","journal-title":"Leukemia"},{"key":"51244_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/10715761003667554","volume":"44","author":"GY Liou","year":"2010","unstructured":"Liou, G. Y. & Storz, P. Reactive oxygen species in cancer. Free Radic Res 44, 479\u2013496, https:\/\/doi.org\/10.3109\/10715761003667554 (2010).","journal-title":"Free Radic Res"},{"key":"51244_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11060-007-9421-4","volume":"85","author":"E Liu","year":"2007","unstructured":"Liu, E. et al. Curcumin induces G2\/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol 85, 263\u2013270, https:\/\/doi.org\/10.1007\/s11060-007-9421-4 (2007).","journal-title":"J Neurooncol"},{"key":"51244_CR24","first-page":"1225","volume":"15","author":"C Park","year":"2006","unstructured":"Park, C. et al. Induction of G2\/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncol Rep 15, 1225\u20131231 (2006).","journal-title":"Oncol Rep"},{"key":"51244_CR25","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.febslet.2008.06.048","volume":"582","author":"WZ Wang","year":"2008","unstructured":"Wang, W. Z., Cheng, J., Luo, J. & Zhuang, S. M. Abrogation of G2\/M arrest sensitizes curcumin-resistant hepatoma cells to apoptosis. FEBS Lett 582, 2689\u20132695, https:\/\/doi.org\/10.1016\/j.febslet.2008.06.048 (2008).","journal-title":"FEBS Lett"},{"key":"51244_CR26","doi-asserted-by":"crossref","unstructured":"Weir, N. M. et al. Curcumin induces G2\/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 6, 178-184 (2007).","DOI":"10.4161\/cbt.6.2.3577"},{"key":"51244_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/01.cmr.0000129374.76399.19","volume":"14","author":"M Zheng","year":"2004","unstructured":"Zheng, M., Ekmekcioglu, S., Walch, E. T., Tang, C. H. & Grimm, E. A. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2\/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 14, 165\u2013171 (2004).","journal-title":"Melanoma Res"},{"key":"51244_CR28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1139\/o90-197","volume":"68","author":"RL Noble","year":"1990","unstructured":"Noble, R. L. The discovery of the vinca alkaloids\u2013chemotherapeutic agents against cancer. Biochem Cell Biol 68, 1344\u20131351 (1990).","journal-title":"Biochem Cell Biol"},{"key":"51244_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00001813-199112000-00002","volume":"2","author":"WJ Slichenmyer","year":"1991","unstructured":"Slichenmyer, W. J. & Von Hoff, D. D. Taxol: a new and effective anti-cancer drug. Anticancer Drugs 2, 519\u2013530 (1991).","journal-title":"Anticancer Drugs"},{"key":"51244_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543776.2016.1111872","volume":"26","author":"I Ojima","year":"2016","unstructured":"Ojima, I., Lichtenthal, B., Lee, S., Wang, C. & Wang, X. Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat 26, 1\u201320, https:\/\/doi.org\/10.1517\/13543776.2016.1111872 (2016).","journal-title":"Expert Opin Ther Pat"},{"key":"51244_CR31","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.E14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver, B. A. How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell 25, 2677\u20132681, https:\/\/doi.org\/10.1091\/mbc.E14-04-0916 (2014).","journal-title":"Mol Biol Cell"},{"key":"51244_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","volume":"13","author":"E Mukhtar","year":"2014","unstructured":"Mukhtar, E., Adhami, V. M. & Mukhtar, H. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther 13, 275\u2013284, https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0791 (2014).","journal-title":"Mol Cancer Ther"},{"key":"51244_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9, 790\u2013803, https:\/\/doi.org\/10.1038\/nrd3253 (2010).","journal-title":"Nat Rev Drug Discov"},{"key":"51244_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molcel.2014.05.003","volume":"55","author":"Y Johmura","year":"2014","unstructured":"Johmura, Y. et al. Necessary and sufficient role for a mitosis skip in senescence induction. Mol Cell 55, 73\u201384, https:\/\/doi.org\/10.1016\/j.molcel.2014.05.003 (2014).","journal-title":"Mol Cell"},{"key":"51244_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.molcel.2014.05.007","volume":"55","author":"L Krenning","year":"2014","unstructured":"Krenning, L., Feringa, F. M., Shaltiel, I. A., van den Berg, J. & Medema, R. H. Transient activation of p53 in G2 phase is sufficient to induce senescence. Mol Cell 55, 59\u201372, https:\/\/doi.org\/10.1016\/j.molcel.2014.05.007 (2014).","journal-title":"Mol Cell"},{"key":"51244_CR36","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nature03890","volume":"436","author":"C Michaloglou","year":"2005","unstructured":"Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720\u2013724, https:\/\/doi.org\/10.1038\/nature03890 (2005).","journal-title":"Nature"},{"key":"51244_CR37","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1128\/MCB.7.8.2745","volume":"7","author":"C Chen","year":"1987","unstructured":"Chen, C. & Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7, 2745\u20132752 (1987).","journal-title":"Mol Cell Biol"},{"key":"51244_CR38","doi-asserted-by":"crossref","unstructured":"Yoneda-Kato, N., Tomoda, K., Umehara, M., Arata, Y. & Kato, J. Y. Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. Embo J 24, 1739\u20131749 (2005).","DOI":"10.1038\/sj.emboj.7600656"},{"key":"51244_CR39","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nsb1203-980","volume":"10","author":"H Berman","year":"2003","unstructured":"Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. Nat Struct Biol 10, 980, https:\/\/doi.org\/10.1038\/nsb1203-980 (2003).","journal-title":"Nat Struct Biol"},{"key":"51244_CR40","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1073\/pnas.050585797","volume":"97","author":"M Faig","year":"2000","unstructured":"Faig, M. et al. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci USA 97, 3177\u20133182, https:\/\/doi.org\/10.1073\/pnas.050585797 (2000).","journal-title":"Proc Natl Acad Sci USA"},{"key":"51244_CR41","doi-asserted-by":"publisher","first-page":"11242","DOI":"10.1074\/jbc.M113.457002","volume":"288","author":"KK Leung","year":"2013","unstructured":"Leung, K. K. & Shilton, B. H. Chloroquine binding reveals flavin redox switch function of quinone reductase 2. J Biol Chem 288, 11242\u201311251, https:\/\/doi.org\/10.1074\/jbc.M113.457002 (2013).","journal-title":"J Biol Chem"},{"key":"51244_CR42","doi-asserted-by":"publisher","first-page":"13480","DOI":"10.1021\/bi990696c","volume":"38","author":"AD Cameron","year":"1999","unstructured":"Cameron, A. D. et al. Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue. Biochemistry 38, 13480\u201313490 (1999).","journal-title":"Biochemistry"},{"key":"51244_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0022-2836(03)00762-9","volume":"331","author":"JF Couture","year":"2003","unstructured":"Couture, J. F. et al. Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J Mol Biol 331, 593\u2013604 (2003).","journal-title":"J Mol Biol"},{"key":"51244_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1074\/jbc.M116.750299","volume":"292","author":"W Harshbarger","year":"2017","unstructured":"Harshbarger, W. et al. Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. J Biol Chem 292, 112\u2013120, https:\/\/doi.org\/10.1074\/jbc.M116.750299 (2017).","journal-title":"J Biol Chem"},{"key":"51244_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-168","volume":"10","author":"V Le Guilloux","year":"2009","unstructured":"Le Guilloux, V., Schmidtke, P. & Tuffery, P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10, 168, https:\/\/doi.org\/10.1186\/1471-2105-10-168 (2009).","journal-title":"BMC Bioinformatics"},{"key":"51244_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","volume":"12","author":"E Harder","year":"2016","unstructured":"Harder, E. et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. J Chem Theory Comput 12, 281\u2013296, https:\/\/doi.org\/10.1021\/acs.jctc.5b00864 (2016).","journal-title":"J Chem Theory Comput"},{"key":"51244_CR47","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1021\/ci6005646","volume":"47","author":"MJ Vainio","year":"2007","unstructured":"Vainio, M. J. & Johnson, M. S. Generating conformer ensembles using a multiobjective genetic algorithm. J Chem Inf Model 47, 2462\u20132474, https:\/\/doi.org\/10.1021\/ci6005646 (2007).","journal-title":"J Chem Inf Model"},{"key":"51244_CR48","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47, 1739\u20131749, https:\/\/doi.org\/10.1021\/jm0306430 (2004).","journal-title":"J Med Chem"},{"key":"51244_CR49","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49, 6177\u20136196, https:\/\/doi.org\/10.1021\/jm051256o (2006).","journal-title":"J Med Chem"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51244-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51244-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T14:45:11Z","timestamp":1671288311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-51244-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["51244"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-51244-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"4 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14867"}}